Cagrilintide is a long-acting, acylated amylin analogue — a synthetic, structurally modified version of the pancreatic hormone amylin — engineered to engage the amylin and calcitonin receptor family with an extended duration of action. In metabolic research, it has drawn intense interest as a non-incretin tool, frequently studied in parallel with the GLP-1 receptor agonist semaglutide. This article unpacks the underlying amylin biology, the molecular logic behind cagrilintide's design, its receptor pharmacology, and the laboratory handling considerations that matter to research teams. Everything here is framed strictly as receptor pharmacology and research science — this material is for laboratory use only and is not guidance for human or animal use.
To understand cagrilintide, start with the hormone it imitates. Amylin — also called islet amyloid polypeptide (IAPP) — is a 37-amino-acid peptide hormone produced by the beta cells of the pancreas. Crucially, beta cells co-secrete amylin alongside insulin in response to nutrient intake. The two hormones travel together, and researchers often describe them as a complementary pair: insulin and amylin are released in a roughly coordinated ratio after a meal, each contributing distinct signals to whole-body energy regulation.
Where insulin works largely on glucose disposal into tissues, amylin's documented roles in the physiology literature center on satiation signaling, gastric emptying, and the modulation of glucagon. In short, amylin is studied as a hormone that communicates nutrient status to the brain and gut rather than acting primarily on peripheral glucose uptake. This functional separation is exactly why amylin biology became an attractive, non-insulin, non-incretin avenue for metabolic researchers.
Amylin does not have a single, dedicated receptor in the way many hormones do. Instead, its signaling depends on a clever modular arrangement. The core is the calcitonin receptor (CTR), a class B G-protein-coupled receptor. On its own, the calcitonin receptor responds to calcitonin. But when CTR associates with one of three small accessory membrane proteins called receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3), its pharmacology shifts: the CTR–RAMP complex becomes an amylin receptor (designated AMY1, AMY2, AMY3 depending on which RAMP is involved).
This calcitonin receptor + RAMP architecture is the heart of amylin pharmacology. It explains two things that matter for any analogue program. First, amylin analogues tend to show cross-reactivity at calcitonin receptors, because the calcitonin receptor is the shared backbone. Second, the relative expression of different RAMPs across tissues shapes how — and where — an amylin-receptor agonist signals. A molecule like cagrilintide is therefore best described not as a single-target agent but as an agonist of an amylin/calcitonin receptor family.
Native amylin is a difficult molecule to work with. It is prone to aggregation (the "amyloid" in islet amyloid polypeptide is not incidental — human amylin can form insoluble fibrils), and it has a short circulating half-life, measured in minutes. Those two properties make unmodified human amylin impractical as a long-acting research tool. The first-generation amylin analogue pramlintide addressed the aggregation problem through amino-acid substitutions, but it remained short-acting, requiring frequent dosing in the contexts where it was used.
Cagrilintide represents a later design philosophy aimed squarely at duration of action. It is a synthetic amylin analogue carrying two key categories of modification:
The fatty-acid chain on cagrilintide is not there for show. It enables reversible binding to serum albumin, the most abundant protein in blood plasma. This albumin-binding approach is a well-established protraction strategy in peptide engineering — the same general principle used to extend the action of several long-acting peptide therapeutics. By tethering itself transiently to albumin, the peptide is shielded from rapid renal clearance and enzymatic degradation, and it is released slowly back into circulation. The net effect reported in preclinical pharmacokinetic work is a substantially prolonged half-life compared with native amylin or pramlintide, supporting infrequent dosing schedules in experimental models.
The table below summarizes cagrilintide's defining properties at a glance.
| Property | Detail |
|---|---|
| Molecular class | Acylated (lipidated) amylin analogue; synthetic peptide |
| Parent hormone | Amylin / islet amyloid polypeptide (IAPP) |
| Primary targets | Amylin receptors (AMY1/2/3) and the calcitonin receptor |
| Receptor backbone | Calcitonin receptor + RAMP accessory proteins |
| Protraction strategy | Fatty-acid side chain → reversible albumin binding |
| Half-life rationale | Albumin binding slows clearance → long-acting profile |
| Pathway relationship | Distinct from the incretin GLP-1 axis |
| Common research pairing | Semaglutide (the "CagriSema" combination) |
| Physical form (lab) | Lyophilised powder, reconstituted before use |
| Verification | HPLC purity analysis + Certificate of Analysis |
| Status | Research use only — not for human or animal consumption |
In the laboratory, cagrilintide is characterized as a dual amylin and calcitonin receptor agonist. By engaging the CTR–RAMP complexes that constitute the amylin receptors, it reproduces and prolongs amylin-type receptor signaling. Activation of these class B GPCRs is generally coupled to Gs proteins and adenylate cyclase, raising intracellular cyclic AMP (cAMP) — the canonical second-messenger readout researchers use to quantify agonist activity in cell-based assays.
What makes cagrilintide pharmacologically interesting is the breadth of its receptor engagement. Because it hits both the amylin receptors and the underlying calcitonin receptor, its signaling profile differs from agents that selectively favor one configuration. Researchers study how this combined amylin + calcitonin receptor agonism translates into the physiological readouts historically associated with amylin biology in model systems — satiation pathways, gastric motility, and glucagon modulation — while exploiting the molecule's long-acting design to maintain stable receptor occupancy over time.
A critical point for mechanistic clarity: cagrilintide does not act through the GLP-1 receptor. It is not an incretin mimetic. This separation is precisely why it is so frequently studied alongside GLP-1 agonists — the two operate on parallel, non-overlapping receptor systems, which opens the door to combination pharmacology.
This is the comparison that drives much of the current research interest, so it deserves a careful, biology-first treatment.
Semaglutide is a GLP-1 receptor agonist — an incretin mimetic. The incretin hormones (GLP-1 and GIP) are released from the gut in response to nutrient ingestion and act on their own dedicated receptors to enhance glucose-dependent insulin secretion and influence appetite-related circuits. GLP-1 signaling runs through the GLP-1 receptor, another class B GPCR, but one entirely separate from the amylin/calcitonin system.
Cagrilintide, by contrast, is an amylin analogue working through the amylin/calcitonin receptor family. The hormones differ by origin and receptor: amylin is a pancreatic beta-cell hormone co-secreted with insulin and signaling via CTR + RAMP; the incretins are gut-derived hormones signaling via their own incretin receptors. In other words, these are two distinct nutrient-sensing axes that evolved to communicate overlapping but non-identical information about energy status.
The research logic for combining them is straightforward: if amylin and incretin pathways are mechanistically complementary, engaging both simultaneously could produce additive or synergistic effects on the metabolic readouts under study — effects that neither pathway achieves alone. The experimental combination of cagrilintide plus semaglutide is the molecule pairing widely referred to as "CagriSema", and it is investigated specifically to interrogate this amylin-plus-incretin hypothesis in metabolic research.
The table below contrasts the two mechanisms.
| Feature | Cagrilintide (amylin analogue) | Semaglutide (GLP-1 agonist) |
|---|---|---|
| Pharmacological class | Amylin analogue / amylinomimetic | Incretin mimetic / GLP-1 receptor agonist |
| Mimicked hormone | Amylin (IAPP), a pancreatic hormone | GLP-1, a gut incretin hormone |
| Hormone origin | Pancreatic beta cells (with insulin) | Enteroendocrine L-cells of the gut |
| Primary receptor(s) | Amylin receptors (CTR + RAMP); calcitonin receptor | GLP-1 receptor |
| Receptor family | Class B GPCR (calcitonin-receptor backbone) | Class B GPCR (GLP-1 receptor) |
| Signaling axis | Amylin / calcitonin axis | Incretin axis |
| Long-acting strategy | Acylation → albumin binding | Acylation → albumin binding |
| Research relationship | Studied alone and combined with GLP-1 agonists | Studied alone and combined with amylin analogues |
| Combination shorthand | Part of "CagriSema" | Part of "CagriSema" |
Notice that both molecules use an acylation/albumin-binding protraction strategy — a shared engineering approach despite their unrelated receptor targets. That convergence is a nice illustration of how peptide design principles transfer across target classes even when the underlying biology is completely different.
Research-grade cagrilintide is supplied as a lyophilised (freeze-dried) powder. Lyophilisation is standard for research peptides because removing water dramatically improves stability and shelf life for a molecule that would otherwise be vulnerable to hydrolysis and aggregation in solution. The following points describe laboratory-level handling only and are written for trained research personnel working with reagents in vitro or in approved model systems — they are not instructions for any human or animal use.
Reconstitution. At the bench, lyophilised peptide is typically brought into solution with an appropriate sterile solvent — commonly bacteriostatic or sterile water, selected to match the experimental protocol and the peptide's solubility. Solvent should be added gently down the side of the vial rather than directed forcefully onto the peptide cake, and the vial swirled rather than shaken, to minimize mechanical stress and foaming that can degrade peptide integrity.
Storage. As a general rule for acylated research peptides:
Because cagrilintide relies on a precise sequence and an intact fatty-acid moiety for its function, maintaining a robust cold chain from supplier to freezer is not a nicety — it is fundamental to getting reproducible data.
For any peptide used in research, identity and purity are everything. Trace deletion sequences, incomplete acylation, residual synthesis reagents, or degradation products can all confound experimental results and undermine reproducibility. Reputable suppliers therefore characterize each batch using analytical methods and provide the documentation to prove it.
The two pillars of verification are:
These analyses are summarized in a Certificate of Analysis (COA) — the batch-specific document that records purity, identity, and quality data. When sourcing research-grade cagrilintide, insist on a current COA. A supplier's willingness to provide batch-level HPLC data and mass-spec confirmation is one of the clearest signals of product quality and a prerequisite for defensible, reproducible research.
You can find related compounds and additional metabolic research peptides in our Weight-Loss & Metabolic peptides category.
Cagrilintide is a long-acting, acylated amylin analogue — a synthetic, structurally stabilized version of the pancreatic hormone amylin (IAPP). It acts as an agonist at the amylin and calcitonin receptor family and carries a fatty-acid side chain that promotes albumin binding to extend its duration of action. It is studied as a research compound in metabolic pharmacology and is supplied for laboratory use only.
"CagriSema" is the informal name for the experimental research combination of cagrilintide (an amylin analogue) plus semaglutide (a GLP-1 receptor agonist). The pairing is studied to investigate how the amylin/calcitonin pathway and the incretin (GLP-1) pathway — two distinct nutrient-sensing axes — interact when engaged together. It is a subject of metabolic research, not a consumer product.
They target completely separate receptor systems. Cagrilintide is an amylin analogue acting on amylin receptors (calcitonin receptor + RAMP accessory proteins). Semaglutide is an incretin mimetic acting on the GLP-1 receptor. Amylin is a pancreatic hormone co-secreted with insulin; GLP-1 is a gut-derived incretin. Because their mechanisms are distinct and potentially complementary, the two are frequently studied together.
The amylin receptor is not a single standalone protein. It is formed when the calcitonin receptor (CTR) — a class B GPCR — associates with a RAMP accessory protein (RAMP1, 2, or 3), producing the amylin receptor subtypes AMY1, AMY2, and AMY3. Cagrilintide is characterized as a dual amylin and calcitonin receptor agonist, engaging both the amylin-receptor complexes and the underlying calcitonin receptor.
Lyophilised cagrilintide is best stored frozen (commonly at or below −20 °C), protected from light and moisture. Once reconstituted, it is generally kept refrigerated (2–8 °C) for short-term use or frozen in aliquots for longer storage, avoiding repeated freeze–thaw cycles. These are laboratory handling notes only and do not constitute guidance for any human or animal use.
When you source cagrilintide for research, quality verification should be non-negotiable. Alluvia Peptides supplies research-grade peptides characterized to high analytical standards:
Explore the product page for Cagrilintide 5mg, or browse the full Weight-Loss & Metabolic peptides category for related research compounds.
Research use only — not for human consumption. This article is provided for educational and informational purposes and describes cagrilintide strictly in terms of receptor pharmacology and laboratory research. Cagrilintide is not approved for human or animal use, is not a drug, supplement, or medical treatment, and must not be used for diagnostic, therapeutic, or consumption purposes of any kind. All handling described refers to controlled laboratory work performed by qualified personnel under appropriate institutional oversight. Nothing here is medical advice or a claim of safety or efficacy in humans.